Eli Lilly and Company Stock News

Eli Lilly (LLY -2.70%) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%.

Tobacco giant Altria (MO -1.77%) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%. But it comes with risks, as its business has been struggling to grow in recent years, and its rate of dividend increases has been modest.

Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, the active ingredient in Lilly's obesity drug Zepbound and diabetes drug Mounjaro, was largely supposed to stop last month.

Pharmaceutical powerhouse Eli Lilly (LLY 0.37%) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for treating type 2 diabetes and Zepbound for chronic weight management.

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.